Key Specifications Table
|Empirical Formula||CAS #|
Pricing & Availability
An invalid quantity was specified. The product quantity has been adjusted.
|444152-5MG||Glass bottle||5 mg||
|Overview||A cell-permeable and highly potent active enantiomer of Nutlin-3 (Cat. No. 444143) that binds to the p53-binding pocket and blocks the interaction of p53 and MDM2 (IC50 = 90 nM). Exhibits over 150-fold greater affinity for MDM2 than its less active enantiomer, Nutlin-3b. Induces p53 mediated apoptosis by both transcription-dependent and independent mechanisms. Shown to greatly potentiate the cytotoxic effects of chemotherapeutic agents and reduce tumor burden in vivo. Also shown to overcome ATM-mediated resistance to fludarabine in chronic lymphocyte leukemia. Cells treated with Nutlin-3a permanently lose their ability to proliferate and enter into a pattern of permanent senescence. Mouse embryonic fibroblasts with p53+/+MEFs show significantly reduced reprogramming capabilities following Nutlin-3a treatment.|
|Structure formula Image|
|Purity||≥98% by HPLC|
|Safety Information according to GHS|
|Product Usage Statements|
|Packaged under inert gas||Packaged under inert gas|
|Ohnstad, H.O., et al. 2011. BMC Cancer 11, 211.
Shen, H. and Maki, C.G., 2010. J. Biol. Chem. 285, 23105.
Kawamura, T., et al. 2009. Nature 460, 1140.
Kojima, K., et al. 2006. Blood 108, 993.
Laurie, N.A., et al. 2006. Nature 444, 61.
Tovar, C., et al. 2006. Proc. Natl. Acad. Sci. USA 103, 1888.
Vassilev, L.T. 2006. Trends Mol Med. 13, 23.
Thompson, T., et al. 2004. J. Biol. Chem. 279, 53015.
Vassilev, L.T., et al. 2004. Science 303, 844.
Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.